Volume : 09, Issue : 06, June – 2022



Authors :

Jeetendra Harijan, Shailendra Modi, Sanjay Jain, Dr. Vijay Nigam

Abstract :

The aim of present investigation was to formulate and evaluate floating tablet of telmisartan. Telmisartan is a non-peptide angiotensin II receptor antagonist. Telmisartan blocks the vasoconstriction and aldosterone secreting effects of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, leading to a reduction in arterial blood pressure. The poor bioavailability of Telmisartan (40-58%) was the criteria which caused the selection of drug, which could be increased by prolonging the gastric retention time so that it remain in the acid environment until all the drug is released. U.V. Scanning of Telmisartan was performed and the λmax at 295 nm was found to be the most appropriate for the determination of concentration of unknown samples. Standard curve of telmisartan was prepared at in 0.1N HCl and the correlation was found to be 0.992 respectively. The tablets of various formulations of telmisartan were prepared and the tablet hardness was found to be in range of 3.01 to 8.24 kg/cm3. The average weight of the prepared tablets of various formulations was found to be with in the Pharmacopoeial limit i.e. ± 7.5% The average percentage (%) drug content was also found with in the Pharmacopoeial limit and shows the effectiveness of the mixing procedure. Formulation F4, F8, F12 having 12 mg MKG content were showing 72.37±2.78, 69.23±2.72, 68.87±3.89 cumulative drug release in 12 hrs. in case of formulations F1, F1, F5, F9, having katira gum content 9 mg were showing 83.52±2.22, 81.56±2.47, 82.71±2.95. From the results obtained, it was concluded that the formulation F7 is the best formulations as the extent of drug release was found to be around 75.44%. This batch also showed immediate floatation and floatation duration of more than 8hr. The drug release model of this formulations comply with Peppas model kinetics.
KEYWORDS: Telmisartan, Gond Katira., Avicel-101, 0.1 N HCl , Methanol, Magnesium sterate, Talc

Cite This Article:

Please cite this article in press Jeetendra Harijan et al, Formulation And Evaluation Of Floating Tablet Of Telmisartan., Indo Am. J. P. Sci, 2022; 09(6).,

Number of Downloads : 10


1) Kuccherkar, B.S., Badhan, A.C., Mahajan, H.S., Mouth dissolving tablets: A novel drugdelivery system, Phrma. Times, 2003, 35, 3-10.
2) Amin, A.F., Shah, T.J., Bhadani, M.N., Patel, M.M., Emerging trends in orally disintegrating tablets, www.pharminfo.net, 2005.
3) Lailla, J.K., Sharma, A.H., Freeze-drying and its applications, Indian Drugs, 1993, 31, 503-513.
4) Seager, H., Drug delivery products and zydis fast dissolving dosage form, J. Pharm. Phamacol., 1998, 50, 375-382.
5) Renon, J.P., Corveleyn, S., Freeze-dried rapidly disintegrating tablets, US Patent No. 6,010,719, 2000.
6) Masaki, K., Intrabuccaly disintegrating preparation and production there of, US Patent No.5,466,464, 1995.
7) Pebley, W.S., Jager, N.E., Thompson, S.J., Rapidly disintegrating tablets, US Patent No. 5,298,261, 1994.
8) Allen, L.V, Wang, B., Method of making a rapidly dissolving tablet. US Patent No. 5,635,210, 1997.
9) Allen, L.V, Wang, B., Process for making a particulate support matrix for making rapidly dissolving tablets. US Patent No. 5,587,180, 1996.
10) S. S. Biradar, S. T. Bhagavati and I. J. Kuppasad, Fast Dissolving Drug Delivery Systems: A Brief Overview, Internet J. Pharmacology, 2006, 4(2).
11) Lachmann, L., Liebermann, H.A., Kiang, J.L., The theory and practice of Industrial Pharmacy, 3rd Ed., Varghese Publishing House, Bombay, 1998, 430-440.
12) Kaushik, D, Dureja, H, Saini, T. R., Mouth Dissolving Tablets: A review. Indian Drugs, 2004, 41(4), 187-193.
13) Yarwood, R.J., Kearny, K., Thomson A.R., Process for preparing solid dosage form for unpalatable pharmaceuticals, US Patent No. 5,738,875, 1998.
13) Arora S, Ali A, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: A review. AAPS PharmSciTech 2005; 6(3): E372‐ E390.
14) Chien YW. Rate‐control drug delivery systems: controlled release vs. sustained release. Med Prog Techn 1989; 15: 21‐46.
15) Chien YW. Oral drug delivery and delivery system in novel drug delivery Systems, ed, 50, Marcel Dekker publication, New York, 1992.
16) Patel GM. Floating drug delivery system: An innovative approach to prolong gastric retention. www.pharmainfo.net, 2007.
16) Koner P, Saudagar RB, Dharwal J. Gastro‐retentive drugs anovel approach towards floating therapy inhttp://www.pharmainfo.net/exlusive/reviews/gastroretentivedrugs a novel approach towards floating therapy, 2007
17) Wilson CG, Washington N. The Stomach: its role in oral drug delivery. In: Rubinstein, M.H., (Ed.). Physiologicalpharmaceutics: biological barriers to drug absorption. EllisHarwood, Chechester, 1989: 47‐70.
18) Desai S. A Novel Floating Controlled Release Drug DeliverySystem Based on a Dried Gel Matrix Network [master’sthesis], Jamaica, NY: St John’s University; 1984.
19) Davis SS, Stockwell AF, Taylor MJ. The effect of density on thegastric emptying of single‐and multiple‐ unit dosage forms,Pharm Res 1986; 3: 208‐ 213.
20) Oth M, Franze M, Timmermans J, Moes A, The bilayer‐floatingcapsule: a stomach directed drug delivery system formisoprostol. Pharm Res 1992; 9: 298‐302.
21) Timmermans J, Gasnsbeka BV, Moes A. Accessing by gammascintigraphythe in vivo buoyancy of dosage form having knownsize and floating force profiles as a function of time. PharmTech 1989; 1: 42‐51.
22) Gergogiannis YS, Rekkas DM, Dallos PP, Chailis NH. Floatingand swelling characteristics of various excipients used incontrolled release technology. Drug Dev Ind Pharm 1993; 19:1061‐1081.
23) Cargill R, Cadwell LJ, Engle K, Fix JA, Porter PA, Gardner CR.Controlled gastric emptying: I. Effects of physical properties ongastric residence times of non disintegrating geometric shapesin beagle dogs. Pharm Res 1988; 5: 533‐536. 24) Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int J Pharm 2003; 253: 13‐22.